WeVote
Log In

Bill

Bill

S 284

An act relating to possessing and dispensing regulated drugs

2025-2026 Regular Session Introduced by Tanya Vyhovsky

Regulates who may possess and dispense regulated drugs, requiring credentials, proper prescribing, patient labeling, records, and enforcement to improve public safety.

Read 1st time & referred to Committee on Judiciary
0
WeVote Research Nonpartisan
Bill Summary · S 284

Summary of Bill S. 284 (Vermont, 2025-2026) — An act relating to possessing and dispensing regulated drugs

Purpose and intent

  • S. 284 is proposed legislation in Vermont that focuses on the possession and dispensing of regulated drugs. The bill aims to establish or modify standards, restrictions, and enforcement related to regulated substances, with the goal of clarifying lawful possession, prescribing, and dispensing practices and addressing public safety concerns associated with regulated drugs.

Key provisions and changes (highlights)

  • Regulation of possession: The bill sets forth rules governing who may possess regulated drugs and under what circumstances, including any necessary credentials, licenses, or prescriptions.
  • Regulation of dispensing: It outlines requirements for dispensing regulated drugs, such as who may dispense, in what settings (e.g., pharmacies, clinics), and the process by which drugs must be dispensed (prescription verification, recordkeeping, labeling, and disclosures to patients).
  • Prescription and practitioner requirements: The bill may specify qualifications for prescribers, limits on quantity or dosage, and conditions under which prescriptions are valid or subject to monitoring.
  • Records and reporting: Provisions likely impose or refine recordkeeping obligations, prescription monitoring, and reporting to applicable state databases or agencies to prevent misuse or diversion.
  • Compliance and enforcement: The act would designate enforcement mechanisms, penalties for violations, and potential licensing or disciplinary actions for noncompliance.
  • Public safety and fraud prevention: Provisions may address illicit possession, diversion, counterfeit prescriptions, or fraud related to regulated substances, including cooperation with law enforcement and regulatory boards.
  • Administrative or rulemaking authority: The bill could authorize relevant state agencies (e.g., health, professional licensing, judiciary) to implement rules or guidelines necessary to enforce the new provisions.

Who would be affected

  • Practitioners and entities authorized to prescribe or dispense regulated drugs (physicians, nurse practitioners, pharmacists, clinics, and hospitals) may need to comply with new standards.
  • Patients and consumers: individuals who receive prescriptions for regulated drugs would be subject to updated prescribing, dispensing, labeling, and recordkeeping requirements.
  • Regulatory and licensing bodies: state agencies responsible for health, professional licensing, and judiciary oversight may gain new authority to regulate, monitor, and enforce compliance.
  • Law enforcement: enhanced enforcement provisions could influence how violations are investigated and prosecuted.

Procedural and timeline aspects

  • Introduction and referral: The bill was read 1st time and referred to the Committee on Judiciary on January 21, 2026.
  • Sponsorship: Co-sponsored by Tanya Vyhovsky.
  • Next steps: The Judiciary Committee will hold hearings, amend as needed, and vote on whether the bill should progress. If approved, it would advance to further readings and eventual floor votes, then to the other chamber (as applicable) and potentially to the governor for signature.

Potential considerations and questions

  • Specific definitions: What constitutes a “regulated drug” under this act, and how does it align with federal schedules?
  • Penalties: What are the exact sanctions for violations, and how do they balance public safety with access to necessary medications?
  • Interaction with existing programs: How does S. 284 interact with Vermont’s Prescription Monitoring Program and other public health initiatives?
  • Implementation burden: What are the costs and administrative requirements for pharmacies, clinics, and prescribers to comply?

Note: The summary reflects the information available from the bill’s title, caption, sponsor information, and the 1st-reading action history. For precise language, scope, definitions, and statutory amendments, consult the bill’s text and fiscal notes as released by the Vermont Legislature.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.